Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bolder Receives $1.2m NIH Grant
Bolder BioTechnology (Bolder) has been awarded a $1.2m phase II Small Business Innovation Research (SBIR) grant, entitled ‘Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease,’
Bolder BioTechnology (Bolder) has been awarded a $1.2m phase II Small Business Innovation Research (SBIR) grant, entitled ‘Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease,’
Juvaris BioTherapeutics (Juvaris) has completed the first close on its Series B equity financing of up to $25m led by SV Life Sciences (SVLS) along with existing investor,
China Aoxing Pharmaceutical (China Aoxing) has reported that its Clinical Trial Application (CTA) for Tilidine/Naloxone Capsules, an opioid drug with abuse resistance property, was officially approved by the
YM BioSciences has reported that nimotuzumab has been approved for marketing in Mexico. YM BioSciences also announced that it has enrolled the first two patients in its randomised,
Burnham Institute for Medical Research and the Sarah W Stedman Nutrition and Metabolism Center at Duke University Medical Center have reported a new collaborative research program that will
Hyperion Therapeutics (Hyperion) has reported that its investigational product HPN-100 (glycerol phenylbutyrate) has received orphan product designation from the FDA for intermittent or chronic treatment of patients with
Johnson & Johnson and Elan Corporation (Elan) have reported that Janseen Alzheimer Immunotherapy has completed the acquisition of substantially all of the assets and rights of Elan related
A new study conducted by Thomas Shea and his team of scientists demonstrated that MemoryXL previously shown to improve cognitive performance in Alzheimer’s disease on adults without dementia.
The US Patent & Trademark Office (PTO) has issued a “Notice of Allowance” in OSI Pharmaceuticals’ (OSI) reissue application for US Patent No 5747498 (the ‘498) composition of
Gentium has reported a total revenue of E2.61m for the second quarter ended June 30, 2009, compared to E1.86m for the second quarter of 2008. The increase is